Study Purpose:
The study will generate data on safety, tolerability and pharmacokinetics after multiple daily doses of CK-2017357 in patients with ALS. Patients will be randomized into one of four different treatment groups, receiving daily oral doses of either placebo, 125 mg, 250 mg, or 375 mg of CK-2017357 for 14 days.Study Status:
Not recruiting
Disease:
Amyotrophic Lateral Sclerosis
Study Type:
Interventional
Type of Intervention:
Drug
Intervention Name:
Placebo (Part A), CK-2017357 (Part A), Riluzole 50 MG (Part B), Placebo (Part B), CK-2017357 (Part B)
Placebo:
Phase:
Phase 2
Study Chair(s)/Principal Investigator(s):
Jeremy Shefner, MD, PhD, State University of New York - Upstate Medical University
Clinicaltrials.gov ID:
Neals Affiliated?
No
Coordinating Center Contact Information
Cytokinetics
280 East Grand Avenue
California, 94080 United States
Full Study Summary:
In Part B, approximately additional 24 patients will be randomized to one of four different treatment groups as in Part A. Patients in Part B will be required to decrease their riluzole dose to 50 mg once a day (QD) for 7 days prior to randomization. After this 7 day period, patients will take riluzole at 50 mg QD concurrently with their morning dose of blinded study drug.
Study Sponsor:
Cytokinetics
Participant Duration:
21 days
Estimated Enrollment:
49
Estimated Study Start Date:
05 / 31 / 2011
Estimated Study Completion Date:
03 / 01 / 2012
Posting Last Modified Date:
05 / 07 / 2019
Date Study Added to neals.org:
06 / 22 / 2011
Minimum Age:
18 Years
Maximum Age:
N/A
Key Inclusion Criteria:1. Able to comprehend and willing to sign an Informed Consent Form (ICF)
2. Males or females 18 years of age or older
3. A diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS according to the World Federation of Neurology El Escorial criteria)
4. Maximum voluntary grip strength in at least one hand between 10 & 40 pounds (females) and 10 & 60 pounds (males)
5. Upright Slow Vital Capacity (SVC) >50% of predicted for age, height, and sex
6. Able to swallow tablets with water
7. Willing and able to remain off riluzole for 4 weeks (Part A only)
8. Currently taking and tolerating a stable dose of 50 mg BID riluzole (Part B only)
9. Willing and able to reduce daily dose of riluzole to 50 mg for 4 weeks (Part B only)
10. Willing and able to refrain from caffeine-containing products during study participation
11. Willing and able to remain off warfarin and theophylline-containing medications during study participation
12. Has a caregiver who is capable of observing and reporting patient status, and also assisting in the proper use of nocturnal oximetry equipment
13. Able to perform pulmonary function tests
Key Exclusion Criteria:
1. Life expectancy <3 months
2. Participation in any trial in which receipt of investigational study drug occurred within 30 days or 5 half-lives of the prior agent, whichever is greater, prior to dosing
3. Any prior treatment with CK-2017357
4. Use of non-invasive positive pressure ventilation (NIPPV) for any part of the day or night
Other protocol-defined inclusion/exclusion criteria may apply.
California Pacific Medical Center
San Francisco, California
94115
United States
Mayo Florida
Jacksonville, Florida
32224
United States
University of Kansas
Kansas City, Kansas
06053
United States
Johns Hopkins Hospital
Baltimore, Maryland
21287
United States
Columbia University Medical Center
New York, New York
10032
United States
SUNY Upstate Medical Center
Syracuse, New York
13210
United States
Carolinas Neuromuscular ALS-MND Center
Charlotte, North Carolina
28207
United States
Penn State Hershey Medical Center
Hershey, Pennsylvania
17033
United States
Drexel University College of Medicine
Philadelphia, Pennsylvania
19107
United States